Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14394185 | 1.00 | GPR84 (0.34) | GPR84ALDH1A1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL22042208 | 1.00 | GPR84 (0.34) | GPR84ALDH1A1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL11422586 | 0.83 | GPR84 (0.36) | GPR84 | |
| SCHEMBL6965861 | 0.82 | — | — | |
| SCHEMBL13947268 | 0.80 | NFKB1 (0.37) | GPR84MAPK1 | |
| SCHEMBL15450820 | 0.79 | GPR84 (0.34) | GPR84 | |
| SCHEMBL7116887 | 0.79 | GPR84 (0.37) | GPR84 | |
| SCHEMBL13969444 | 0.79 | ALDH1A1 (0.37) | ALDH1A1TSHRHSD17B10 | |
| SCHEMBL14101244 | 0.78 | — | — | |
| SCHEMBL18598921 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4227312-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | Lg Chem, Ltd. (KR) | 2023-08-16 | — | — | EP | disclosed |
| EP-2934540-B1 | METHODS FOR TREATING GI TRACT DISORDERS | NEUROGASTRX INC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3862350-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | LG Chem, Ltd. (KR) | 2021-08-11 | — | — | EP | disclosed |
| US-9884830-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-02-06 | — | — | US | disclosed |
| US-20120093560-A1 | PACKAGING AND APPLICATOR DEVICE FOR AT LEAST ONE SOLID COSMETIC COMPOSITION | L'OREAL (FR) | 2012-04-19 | — | — | US | disclosed |
| US-20110009371-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| WO-2008124150-A1 | METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-10-16 | — | — | WO | disclosed |
| US-7196150-B2 | Method for radical polymerisation in the presence of a chain transfer agent | BASF AKTIENGESELLSCHAFT (DE) | 2007-03-27 | — | — | US | disclosed |
| US-20060058478-A1 | Method for radical polymerisation in the presence of a chain transfer agent | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-16 | — | — | US | disclosed |
| US-5880101-A | TREATMENT OF DISEASES ASSOCIATED WITH AN IMPAIRED ENERGY TURNOVER; STIMULATING ENERGY CONVERSION IN HUMAN CELLS | DR. ZERLE GMBH (DE) | 1999-03-09 | — | — | US | disclosed |
| WO-1995002411-A1 | STABILISED POLYPEPTIDE GROWTH FACTOR FORMULATION AT LOW PH | MALLINCKRODT VETERINARY LIMITED (AU) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009371-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | GPR84 4369/4885ALDH1A1 4455/4885CYP3A4 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.